512783-84-5Relevant articles and documents
Azetidinones as vasopressin V1a antagonists
Guillon, Christophe D.,Koppel, Gary A.,Brownstein, Michael J.,Chaney, Michael O.,Ferris, Craig F.,Lu, Shi-fang,Fabio, Karine M.,Miller, Marvin J.,Heindel, Ned D.,Hunden, David C.,Cooper, Robin D.G.,Kaldor, Stephen W.,Skelton, Jeffrey J.,Dressman, Bruce A.,Clay, Michael P.,Steinberg, Mitchell I.,Bruns, Robert F.,Simon, Neal G.
, p. 2054 - 2080 (2007)
The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing h
BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS
-
Paragraph 0114, (2018/02/04)
Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER
-
Page/Page column 49, (2012/01/15)
Compounds and compositions are described herein for treating post tramatic stress disorder.
